Antipsychotics - Articles - Page 14

Are Depot Antipsychotics More Effective than Oral Meds? Maybe

April 1, 2011

Section editor, Glen Spielmans, PhD

Clinical folklore (and occasional drug reps) have suggested that depot antipsychotics have adherence advantages over their oral counterparts.

Atypicals No Better Than Typicals in Depression with Schizophrenia

February 1, 2011

Second generation antipsychotics have developed a reputation for being more effective for treating a number of the symptoms of schizophrenia than their first generation counterparts, even if research doesn’t always back up this claim.

Long Acting Injectable Antipsychotics: A Primer

December 1, 2010

Kelly Gable, PharmD, BCPP and Daniel Carlat, MD

Kelly Gable, PharmD, BCPP Assistant professor of pharmacy practice Southern Illinois University, Edwardsville, School of Pharmacy Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report

They used to be called “depot” antipsychotics, but the powers that be have renamed them “long acting injectables” (LAIs), presumably to help remove some of the stigma associated with their use. But no matter what you call them, suddenly every drug company is racing to introduce its own LAI neuroleptic.

Management of Antipsychotic Induced Weight Gain

December 1, 2010

Caroline Fisher, PhD, MD.

Antipsychotics are effective at many things, including inducing weight gain.

Combined Oral Contraceptives: A General Overview

December 1, 2010

Anne Powell, MD.

Given the teratogenicity of certain psychiatric drugs like mood stabilizers and antipsychotics, it is logical and responsible to offer contraception to patients for whom these drugs are prescribed. However, actually doing so can be complicated.

Side Effects of Antipsychotics in Children

December 1, 2010

At a certain point [in my research career], with all the children and adolescents who were being prescribed psychiatric medications, I thought that the adverse effects of antipsychotics in this young patient population were worth examining.

Can Omega 3s Prevent Psychotic Disorders?

April 1, 2010

Section editor, Glen Spielmans, PhD

Omega 3 fatty acids were once thought to be a possible treatment for mood disorders—but recent studies have been unimpressive.

Saphris and Fanapt: Two New Antipsychotics

December 1, 2009

Heidi W. Ashih, MD, PhD

You've probably heard about Fanapt (iloperidone) and Saphris (asenapine), two antipsychotics that have recently won FDA approval for the acute treatment of schizophrenia, and, in the case of Saphris, for the treatment of manic and mixed episodes of bipolar disorder. Are these more “me too”...

Topics in the Treatment of Schizophrenia

December 1, 2009

Dost Ongur, PhD, MD

TCPR-December-2009-Tx-Schizophrenia_DostOngurMD_headshot.png

Dost Ongur, MD. Clinical Director, Schizophrenia and Bipolar Disorder Program, McLean Hospital
Assistant Professor of Psychiatry , Harvard Medical School
Dr. Ongur has disclosed that he has received free study medication (Riluzole) from Sanofi Aventis for a study on bipolar depres-
sion. Dr. Carlat has found that there is no evidence of commercial bias in this educational activity.

Dr. Ongur, over the past few decades, the dominant theory of schizophrenia has been the dopamine hypothesis, but that has been changing lately. Can give us a quick review of the original hypothesis and then go on to some of the alternative neurochemical theories?

Abilify for Depression and Bipolar Disorder: A Meta-Analysis

November 1, 2009

Section editor, Glen Spielmans, PhD

Abilify (aripiprazole), which has long been FDA-approved for both schizophrenia and manic episodes of bipolar disorder, was recently approved for augmentation of antidepressants in patients with treatment-resistant depression.